Acumen Pharmaceuticals is developing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid-beta oligomers, a primary cause of Alzheimer's disease.

858 Therapeutics raised $50 million in Series B funding, led by Avidity Partners, to advance its pipeline of small-molecule therapeutics.

Interim results from the FINE-REAL study indicate that finerenone is being initiated in routine clinical practice across various settings for patients with CKD and T2D.

A phase 3 trial (GETUG 14) reveals that combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improves disease-free survival in localized prostate cancer patients.

Swissmedic is expected to decide by the end of 2024 whether to approve lecanemab, the first new Alzheimer’s drug in two decades.

CaaMTech received positive feedback from U.S. regulators for its CT-4201 psilocin prodrug program, which includes a strategy for functional unblinding in clinical trials.

The FORESEE trial demonstrated that the CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases, exceeding the target endpoint.

The FDA has approved Danziten (nilotinib), a new formulation of nilotinib, for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

Samsung Bioepis received a positive CHMP opinion for Obodence and Xbryk, biosimilars of Amgen's Prolia and Xgeva, respectively, targeting osteoporosis and skeletal-related conditions.

BrightHeart's AI software has received FDA 510(k) clearance for prenatal ultrasound evaluations of the fetal heart, aiding in the detection of congenital heart defects (CHDs).

NICE has reconsidered its decision for Tofersen, a drug that slows the progression of Motor Neurone Disease (MND) in individuals with the SOD1 genetic change.

Phase 3 trials ICONIC-LEAD and ICONIC-TOTAL showed JNJ-2113 significantly improved skin clearance in moderate to severe plaque psoriasis patients.

Praxis Precision Medicines' PRAX-114 Phase 2/3 clinical trial for Major Depressive Disorder (MDD) is set to begin in March 2021 after IND clearance.

Medtronic receives FDA clearance for its updated InPen app, designed for use with the Simplera CGM system, enhancing its smart multiple daily injection (MDI) system.

Merck's Winrevair significantly reduced the risk of death in patients with pulmonary arterial hypertension, marking a potential breakthrough in treating this rare lung condition.

The FDA has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

Science 37 significantly boosted U.S. enrollment in GSK's Phase 3 trial for primary biliary cholangitis (PBC) by utilizing a direct-to-participant model.

Kisunla (lecanemab), an FDA-approved drug, offers hope by targeting and breaking down amyloid plaques in the brain, which are associated with Alzheimer's disease.

Ultromics' artificial intelligence (AI) software has secured FDA approval for the diagnosis of cardiac amyloidosis, offering a new tool for identifying the disease.

Several companies are actively involved in developing therapies for Hemophilia B, with Belief Biomed's drug candidates reaching Phase III clinical trials.